bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Business Wire
October test volume 111% more than 2025 year-to-date monthly average SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued sales growth of its noninvasive lung cancer diagnostic test, CyPath® Lung, with the number of tests processed increasing steadily each month and more than doubling since the start of 2025. October’s test volume increased by 111% over the 2025 monthly average.“The increase in CyPath® Lung test volume demonstrates that physicians are increasingly recognizing the clinical value of CyPath® Lung in detecting lung cancer at its earliest and most treatable stages,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “This steady adoption of our test underscores the success of our outreach to pulmonologists, health systems, and VA medical centers, as well as the growing trust among c
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer RoundtableBusiness Wire
- bioAffinity Technologies Reports Third Quarter 2025 Financial ResultsBusiness Wire
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung DiseasesBusiness Wire
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025Business Wire
- bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer [Yahoo! Finance]Yahoo! Finance
BIAF
Sec Filings
- 12/3/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- BIAF's page on the SEC website